DataMeds AI unit reports $600K monthly revenue and new GLP-1 drugs

DataMeds AI, Inc. (NASDAQ: MEDS) reported that its pharmacy subsidiary, Corexa Pharmacy, generated more than $600,000 in revenue in July 2026, placing its annualized run rate above $7 million, according to a press release from the company.

Corexa Pharmacy, recently rebranded from Wellgistics Pharmacy, has registered with TrumpRx to offer patients access to oral GLP-1 agonist drugs, including Eli Lilly's Foundayo and Novo Nordisk's oral Wegovy, with out-of-pocket costs starting at $149. Injectable GLP-1 agonist drugs are also now available through the pharmacy.

The company said it has integrated its online store, CorexaRx.com, into the Health Lives Here mobile app, available on Apple App Store and Google Play. The app was introduced at the 2026 Pro Football Hall of Fame Game and is currently accessible exclusively to former NFL players. A public rollout is expected in September 2026, beginning in North Carolina.

Through the app, patients can conduct telemedicine visits, receive or refill GLP-1 agonist prescriptions, and monitor health data over time. The company said it plans to support the launch with an influencer campaign led by former NFL players in partnership with NFL Alumni Health.

Corexa Pharmacy has also made available Forzet, a medical food manufactured by Tollo Health, LLC, intended to help manage muscle loss associated with weight loss therapies. Additional products now available include medical food Galectovid and dietary supplement Tollovid, both from Tollo Health, targeting customers with acute and chronic viral infections.

Interim co-CEO Gerald Commissiong said the company believes it is positioned to drive growth through its telemedicine platform, with an initial focus on GLP-1 users, as the Health Lives Here app becomes more broadly available.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• BMO on Enbridge (ENB): 'we do not expect a material change in long-term growth priorities'
• ServiceTitan (TTAN) call put ratio 1.6 calls to 1 put into quarter results